Assessment of Safety and Satisfaction Toward COVID-19 Vaccines.
May 21, 2023 updated by: Rehab Werida, Damanhour University
Assessment of Safety and Satisfaction Toward COVID-19 Vaccines: A Cross-sectional Study.
This is a cross-sectional, web-based online survey done with the use of a Google Form-questionnaire to gather information from the general public regarding their knowledge, satisfaction, and tolerability about the COVID-19 vaccine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- A cross-sectional study was conducted. The subjects participating in the study are residents in Egypt.
- An online questionnaire, designed on Google Forms, was written in Arabic language and delivered to participants via social media (primarily Facebook, WhatsApp and Linkedin).
- The questionnaire comprised two categories of inquiries. The first is demographic data of the subject. The second is questions about COVID-19 vaccine-related data, such as whether had taken the vaccine or not, the type of vaccine administered, side effects encountered from the vaccine , if got enough information regarding the vaccine and where obtain the vaccine information from and if reluctant to taking the vaccine and the reasons for hesitancy. All participants were permitted to terminate the survey at any time of the study.
Study Type
Observational
Enrollment (Actual)
508
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Elbehairah
-
Damanhūr, Elbehairah, Egypt, 31527
- Rehab Hussein Werida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The subjects participating in the study are residents in Egypt who complete the online questionnaire.
Description
Inclusion Criteria:
- all adults (age ≥ 18 years) complete the questionnaire were considered eligible to participate in the survey.
Exclusion Criteria:
- Incomplete questionnaires were excluded from the final analysis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
headache incidence
Time Frame: 3 month
|
Pecentage
|
3 month
|
|
fever incidence
Time Frame: 3 month
|
Pecentage
|
3 month
|
|
fatigue incidence
Time Frame: 3 month
|
Pecentage
|
3 month
|
|
pain at site of injection incidence
Time Frame: 3 month
|
Pecentage
|
3 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Rehab H Werida, Ass. Prof., Damanhour University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021 Feb;27(2):225-228. doi: 10.1038/s41591-020-1124-9. Epub 2020 Oct 20. Erratum In: Nat Med. 2021 Jan 11;:
- Malik A, Malik J, Ishaq U. Acceptance of COVID-19 vaccine in Pakistan among health care workers. PLoS One. 2021 Sep 15;16(9):e0257237. doi: 10.1371/journal.pone.0257237. eCollection 2021.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2021
Primary Completion (Actual)
February 1, 2022
Study Completion (Actual)
February 10, 2022
Study Registration Dates
First Submitted
May 10, 2023
First Submitted That Met QC Criteria
May 10, 2023
First Posted (Actual)
May 12, 2023
Study Record Updates
Last Update Posted (Actual)
May 23, 2023
Last Update Submitted That Met QC Criteria
May 21, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVID-19 vaccines Perception
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.